Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Reexamination Certificate
2005-03-15
2005-03-15
Priebe, Scott D. (Department: 1635)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
C435S455000, C435S456000, C435S325000, C435S457000, C435S471000, C435S475000, C435S369000, C435S320100, C424S093200
Reexamination Certificate
active
06867022
ABSTRACT:
The invention provides novel replication deficient adenovirus vectors and methods for making and using these viruses. The invention also provides vector systems and kits using a serotype specific strategy for making adenoviral vector preparations substantially free of replication competent “helper” virus. The helper virus-free preparations provide novel pharmaceutical compositions substantially free of helper virus for use in gene transfer and gene therapy.
REFERENCES:
patent: 5851806 (1998-12-01), Kovesdi et al.
patent: 5880102 (1999-03-01), George et al.
patent: 5882877 (1999-03-01), Gregory et al.
patent: 5891690 (1999-04-01), Massie
patent: 5919676 (1999-07-01), Graham et al.
patent: 5922576 (1999-07-01), He et al.
patent: 5981225 (1999-11-01), Kochanek et al.
patent: 5985846 (1999-11-01), Kochanek et al.
patent: 5994132 (1999-11-01), Chamberlain et al.
patent: 5994134 (1999-11-01), Giroux et al.
patent: 6001557 (1999-12-01), Wilson et al.
patent: 0 955 373 (1999-11-01), None
patent: 0 978 566 (2000-02-01), None
patent: WO 9633280 (1996-10-01), None
patent: WO 9732481 (1997-09-01), None
patent: WO 9813510 (1998-04-01), None
patent: WO 9932647 (1999-07-01), None
patent: WO9941400 (1999-08-01), None
patent: WO 9953085 (1999-10-01), None
T-L Chiu et al.,Folding & Design, “Optimizing energy potentials for success in protein tertiary structure prediction,” May 1998, 3:223-228.*
Rubanyi, The future of human gene therapy, 2001, Molecular Aspects of Medicine, vol. 22, pp. 113-142.*
Imperiale, Molecular biology of adenovirus gene therapy vectors, 2000, Basic Science and Gene Therapy, pp. 119-128.*
Danthinne et al., Production of first generation adenovirus vectors: a review, 2000, Gene Therapy, vol. 7, pp. 1707-1714.*
Hasson et al., Adenovirus L1 52- and 55-kilodalton proteins are required for assembly of virions, 1989, Journal of Virology, pp. 3612-3621.*
Gustin et al., Encapsidation of viral DNA requires the adenovirus L1 52/55-kilodalton protein, 1998, Journal of Virology, pp. 7860-7870.*
Zhang et al., Interaction of the adenovirus IVa2 protein with viral packaging sequences, 2000, Journal of Virology, pp. 2687-2693.*
Schmid et al., Bipartite structure and functional independence of adenovirus type 5 packaging elements, 1997, Journal of Virology, pp. 3375-3384.*
Gustin et al., Interaction of the adenovirus L1 52/55-kilodation protein with the IVa2 gene product during infection, 1996, Journal of Virology, vol. 70, pp. 6463-6467.*
Verma et al., Gene therapy-promises, problems and prospects, 1997, NATURE, vol. 389, pp. 239-242.*
Anderson, Human gene therapy, 1998, NATURE, vol. 392, pp. 25-30.*
Parks et al., “Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration,”Gene Therapy, (1999) 6, 1565-1573.
Mayr et al., “Development of Replication-Defective Adenovirus Serotype 5 Containing the Capsid and 3C Protease Coding Regions of Foot-and-Mouth Disease Virus as a Vaccine Candidate,”Virology263 (1999) 496-506.
Nabel, “Development of optimized vectors for gene therapy,”Proc. Natl. Acad. Sci. USA, vol. 96, (Jan. 1999), pp. 324-326.
Schmid et al., “Cellular components Interact with Adenovirus Type 5 Minimal DNA Packaging Domains,”Journal of Virology(Aug. 1998) p. 6339-6347.
Alemany et al., “Complementation of helper-dependent adenoviral vectors: size effects and titer fluctuations,”Journal of Virological Methods68, (1997) p. 147-159.
Schmid et al., “Bipartite Structure and Functional Independence of Adenovirus Type 5 Packaging Elements,”Journal of Virology(May 1997) p. 3375-3384.
Fechteler et al., “The Mechanism of Adenovirus DNA Integration: Studies in a Cell-Free System,”Curr. Top. Microbial. Immunol. (1995) 199 (Pt. 2): 109-137.
Schmid et al., “Selective Encapsidation of Adenovirus DNA,”Curr. Top. Microbial. Immunol. (1995) 199 (Pt. 1): 67-80.
Grable et al., “cisandtransRequirements for the Selective Packaging of Adenovirus Type 5 DNA,”Journal of Virology(Feb. 1992) p. 723-731.
Medlen & Carroll LLP
Priebe Scott D.
Regents of the University of Michigan
Whiteman Brian
LandOfFree
Replication deficient adenovirus vectors and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Replication deficient adenovirus vectors and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Replication deficient adenovirus vectors and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3420840